Docket No.:

TOYA108.006APC

March 24, 2005 Junger Page 1 of 1

Please Direct All Correspondence to Customer Number 20995

TRANSMITTAL LETTER INFORMATION DISCLOSURE STATEMENT

Applicant

Katunuma, et al.

App. No

10/510,088

Filed

October 4, 2004

For

CYSTEIN PROTEASE INHIBITOR

Examiner

Unknown

Art Unit

Unknown

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 24, 2005

(Date)

Che Swyden Chereskin, Ph.D., Reg. No. 41,466

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing and enclosing 1 reference.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

1439687_1 032405 INFORMATION DISCLOSURE STATEMENT

Applicant

Katunuma, et al.

App. No

10/510,088

Filed

October 4, 2004

For

CYSTEINE PROTEASE INHIBITOR

Examiner

Unknown

Art Unit

Unknown

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 1 reference to be considered by the Examiner. Also enclosed is 1 foreign patent reference and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 24, 2008

) By:_

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

NFORMATION DISCLOSURE 本色MENT BY APPLICANT

Application No. 10/510,088 Filing Date October 4, 2004 First Named Inventor Katunuma, et al. Art Unit Unknown Unknown Examiner Attorney Docket No. TOYA108.006APC

(Multiple sheets used when necessary) SHEET 1 OF 1

Cite

No.

Examiner

Initials

	U.S. PATENT [OCUMENTS	
Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹	
						···	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹		
		Lönnerdal, et al. "Cloning and Sequencing of a cDNA Encoding Human Milk β-Casein," Federation of European Biochemical Societies, Vol. 269, No. 1, pp. 153-156, August, 1990.	,, s,		

1439667_1 032405

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.